First Treatment Approved for Molluscum Contagiosum
Topical cantharidin (Ycanth) was approved as the first treatment specifically…
Browsing Tag
Contagiosum
Following FDA Approval of YCANTH™ for the Treatment of Molluscum Contagiosum, Verrica…
Term loan facility would provide for up to $125M in non-dilutive capital; $50M immediately available to Company following close of the transaction, which is expected to occur by the end of…
Verrica Pharmaceuticals Announces FDA Approval of YCANTH™ (cantharidin) topical…
– Molluscum, is a highly contagious viral skin infection affecting approximately 6 million people annually in the United States, primarily children – – YCANTH™ is a drug-device combination…
At-Home Topical Therapy for Molluscum Contagiosum Gets High Marks
NEW ORLEANS -- Almost 40% of patients with molluscum contagiosum, some with dozens of lesions, had complete or near-complete…
Verrica Pharmaceuticals Announces FDA Acceptance of Filing of Resubmitted NDA for…
<!-- Name:DistributionId Value:8777554 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (SB206)…
– Potential FDA approval anticipated in first quarter 2024, assuming the filing is accepted by the FDA and under standard review timelines – – Molluscum contagiosum is a viral skin…
Novel Nitric Oxide Gel Clears Kids’ Molluscum Contagiosum Lesions
A novel nitric oxide-releasing gel led to significantly more patients achieving complete…
Verrica Pharmaceuticals Announces Acceptance by FDA of NDA Resubmission for VP-102…
WEST CHESTER, Pa., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases…
Verrica Pharmaceuticals Announces Resubmission of New Drug Application for VP-102 for…
WEST CHESTER, Pa., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases…
Novan Reports Positive Topline Results from Pivotal Phase 3 Trial of SB206 in…
– B-SIMPLE4 achieves statistical significance for the primary endpoint with p-value less than 0.0001 – – No serious adverse events related to treatment with SB206 – – Novan intends to…